Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 2025 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, representing a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with plans to continue innovating and introducing new platforms [4][6] - A specialized sales team has been established for the Envision platform, aimed at increasing penetration and improving sales productivity [5] - The company plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases [17] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [13] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [20] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [17] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives and has engaged Bank of America for assistance, with management not directly involved in the process [20] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [72] Question: What is the contribution of new product launches for 2026? - Two new products are expected to be launched in 2026, with significant marketing efforts planned, although specific financial contributions are not yet provided [41]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with expectations for revenue to be broadly in line with 2025 [4][7] - Product innovation is a key pillar of the strategy, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6][7] - The sales force is now segmented across aesthetic and wellness, with a dedicated team for specific platforms to drive increased penetration and improve sales productivity [5] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization in the U.S. and gradual improvement in Europe [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases, which may encourage more sales [16] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [12] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to enhance company value, with management not directly involved in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How significant is the laser market for future growth? - The CEO emphasized that laser platforms are essential for growth, despite being in a saturated market with lower margins compared to existing products [31][32] Question: What is the status of the dry eye indication and FDA approval timelines? - The company is working on FDA approval for a bipolar RF device for dry eye treatment, with studies expected to last through 2026 and possibly into 2027 [64][65]

SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predi ...

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD, with a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a combined implant solution [1] - CICC expresses optimism regarding the approval of this product, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - Looking ahead, CICC believes that the company's research and development strength, brand recognition, and team cohesion remain solid, suggesting that there are opportunities for investment as the cosmetics market recovers and contributions from aesthetic medicine increase [1]

当前，射频抗衰市场在深度调整中迎来结构性变革，如何在竞争红海中确立优势？为找到高能破局之 道，YOUMAGIC舒立缇携手行业共探千万增长新路径，在全国多城举办"千万增长·高能破局"系列战略 解码会。相关会议继在北京、沈阳、西安三城圆满举办后，又在上海、南京、深圳、杭州等地成功引爆 并圆满收官。会议聚焦千万增长目标与100KJ高能临床交付，从技术创新、临床实操到业绩增长、营销 升级全链剖析，为机构破解增长困局提供了实战蓝图。 行业结构性变革新周期，以100KJ高能交付重塑增长逻辑 YOUMAGIC舒立缇的多位区域负责人在系列会议上一致认为，随着消费者对深层紧致与舒适体验要求 的日益提升，射频抗衰领域已迈入"高能量、高显效"的技术竞争新周期。与此同时，机构运营模式也在 向"高客单、高复购、高信任"周期转型。舒立缇搭载100ms闪脉冲技术、多维智能温控及四档可调制冷 等系统，突破了传统射频在能量稳定、热感均匀性及深层作用上的局限，可以实现"高能且不痛"的 100KJ打法，是机构可靠的"现金流引擎"与医生高效的"交付工具"，正重塑行业技术标准与增长逻辑。 在这场技术引领的行业变革中，临床实践是把技术势能转化为增长动能 ...

Company Dynamics - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a recombinant collagen and hyaluronic acid composite solution [1] - The approval of this product is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Comments - The approval of the world's first recombinant collagen and hyaluronic acid composite solution for improving cheek smoothness represents the second medical aesthetic license obtained by the company [2] - The company plans to steadily advance the product's market launch and promotion through a diverse product portfolio, comprehensive channel network, and refined brand operations, aiming to strengthen its leading market position in the health and beauty sector [2] Future Prospects - The company has a rich pipeline of aesthetic medicine products, with the cross-linked neck wrinkle product having received national priority review qualification, and the cross-linked nasolabial fold product progressing smoothly [2] - The successful approval of the first two aesthetic products has validated the company's technological leadership and safety, with strong channel resources and operational experience expected to facilitate the rollout of future products [2] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for its cosmetics product matrix and channel expansion, with a rich reserve of new products, including multiple new offerings from the 可复美胶原修护, 焦点, and 秩序 series planned for launch [2] - The company is also upgrading its 可丽金 brand and plans to introduce new products by 2026, while collaborating with key influencers like Li Jiaqi to enhance marketing efforts [2] - The company aims to strengthen its online presence through influencer partnerships and expand its offline coverage in cinema lines, OTC, and CS/KA channels, as well as its own store layout [2] Profit Forecast and Valuation - The company maintains its net profit forecast for 2025-2026 and introduces a net profit estimate of 2.4 billion for 2027, with the current stock price corresponding to a 16x and 14x P/E for 2026-2027 [2] - The company maintains an outperform rating and a target price of 56 HKD, corresponding to a 25x and 23x P/E for 2026-2027, indicating a potential upside of 55% [2]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the new product, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product portfolio and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product mix, comprehensive channel network, and refined brand management [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Insights - The article highlights the launch of two significant products, the Peninsula Super Cannon and Peninsula Counterclockwise, by Peninsula Medical Group, which recently received NMPA Class III medical device registration [1][3] - These products aim to address deep support and superficial repair in aesthetic medicine, utilizing advanced technology to achieve comprehensive treatment from the fascia layer to the epidermis [1][2] - The company emphasizes its commitment to making advanced medical equipment accessible to thousands of hospitals in China, which were previously dominated by international giants [1] Product Innovations - The Peninsula Golden Microneedle introduces dynamic layered treatment technology, allowing for targeted treatment across five skin layers with a single needle insertion, addressing uneven energy distribution and enhancing patient comfort [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle, resolves the industry challenge of balancing efficacy and comfort through multi-dimensional technological innovations [2] - The Peninsula Super Cannon, the first globally to receive NMPA Class III certification for focused ultrasound skin treatment, boasts a 50% efficiency improvement and integrates high-resolution ultrasound imaging with treatment processes [3] Market Position and Growth - China is identified as the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market share [4] - Following its certification, the Peninsula Super Cannon experienced a surge in search interest, indicating strong market potential and consumer engagement [4] - The company has also secured multiple international certifications, including FDA and CE, positioning itself to compete on a global scale and potentially lead in the medical aesthetic device market [4]

Core Insights - The article highlights the launch of two new medical devices, Peninsula Super Cannon and Peninsula Counterclockwise, which have received NMPA Class III medical device registration and are now certified by FDA and CE, marking a significant step for the company in the global aesthetic medical market [1][2] Company Overview - Peninsula Medical, founded by Lei Xiaobing, aims to make advanced medical equipment affordable for thousands of hospitals in China that were previously dominated by international giants [1] - The company has expanded from Chongqing to Shanghai and finally established its base in Shenzhen, with products now sold in over 70 countries and regions, serving thousands of hospitals and aesthetic institutions [1] - The company boasts a research and development team of nearly 400 people, bridging clinical needs with engineering technology [1] Product Innovations - The Peninsula Super Cannon integrates a high-resolution intelligent ultrasound imaging system with treatment processes, introducing the SOP 3.0 precision treatment system, which allows for visual, quantifiable, and traceable treatment standards [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle device, addresses the industry pain point of balancing efficacy and comfort, utilizing multi-dimensional technological innovations [2] - Key features of the Peninsula Counterclockwise include layered treatment technology, mixed mode output, and a significant increase in energy delivery efficiency, which enhances patient comfort and reduces recovery time [2] Market Potential - According to third-party market research firm, Sullivan, China has become the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market, driving core growth in the industry [3] - The company expresses confidence in the future of Chinese aesthetic medical device enterprises and service institutions becoming global brands [3]

Core Insights - Peninsula Medical is experiencing rapid growth in user trust, with over 1 user receiving anti-aging or skin rejuvenation treatments every minute, and its core products have treated over 4 million users [1] - The company launched two new products, "Peninsula Big Ultrasound" and "Peninsula Counterclockwise," both of which received the highest medical device certification in China [1] - The market for anti-aging treatments in China is rapidly expanding, with 99.7% of consumers considering anti-aging important, creating significant demand for Peninsula's new products [2] Product Performance - The "Peninsula Big Ultrasound" has gained significant market attention since its NMPA III class certification, quickly becoming a trending product on social media [2] - The product's strong market performance is evidenced by high user satisfaction and repeat purchase rates, indicating its potential as a market leader [2][3] - Clinical trials for the "Peninsula Counterclockwise" show over 96% effectiveness in scar improvement and high user satisfaction rates [5][6] Technological Advancements - The "Peninsula Counterclockwise" is the first domestic product to receive both NMPA and FDA certifications, addressing key industry challenges by balancing effectiveness and comfort [4] - The "Peninsula Big Ultrasound" features advanced technology that improves energy efficiency by over 50% compared to previous models, enhancing treatment comfort and precision [5] Industry Impact - Peninsula Medical's commitment to social responsibility is highlighted by its participation in charity auctions, setting a new record in the beauty industry [3] - The company has established a strong research and development foundation, with over 1,000 patent applications and a dedicated team of nearly 400 researchers [7] - Through training programs, Peninsula Medical has certified over 12,000 professional physicians, contributing to the overall improvement of industry standards [8] Strategic Vision - Peninsula Medical aims to lead the high-end medical aesthetics market in China and globally, focusing on long-term growth and innovation [9] - The company emphasizes the integration of scientific research and clinical practice to enhance user experience and product effectiveness [9]